Table 1 Clinical and biochemical characteristics of the NMOSD and control groups under study

Age (years)

35.89 ± 9.39

37.40 ± 6.68

0.24

Sex (Female)

50 (89.3%)

93 (93.0%)

0.42

BMI (kg/m²)

26.61 ± 5.15

26.82 ± 5.45

0.81

History of alcohol consumption (whisky and/or vodka)

2 (3.57%)

1 (1%)

0.26

History of smoking

3 (5.35%)

6 (6%)

0.86

Physical activity (Ln MET-min/week)

7.36 ± 2.09

7.60 ± 1.07

0.38

Duration of the disease (years)

4.16 ± 2.91

–

–

Age of onset (years)

32.28 ± 9.11

–

–

 Azathioprine

13 (23.2%)

 Rituximab

43 (76.8%)

Comorbidity

8 (14.28%)

–

EDSS score^a

3 (3.5)

 FBS (mg/dL)

85.47 ± 6.93

90.42 ± 9.03

0.003

 Ln.HDL (mg/dL)

3.89 ± 0.23

3.93 ± 0.20

0.29

 LDL (mg/dL)

100.71 ± 71

105.97 ± 97

0.27

 Ln.TG (mg/dL)

4.71 ± 0.46

4.57 ± 0.48

0.07

 Chol (mg/dL)

171.75 ± 32.62

177.77 ± 34.67

0.29

 Ln.Insulin (μU/L)

2.78 ± 0.88

2.12 ± 0.48

0.0001

 Ln. SAT (U/L)

3.30 ± 0.28

3.24 ± 0.31

0.15

 Ln.ALT (U/L)

2.94 ± 0.31

2.81 ± 0.45

0.038

 Ln.IL-17 (pg/ml)

2.00 ± 1.18

1.11 ± 0.81

0.0001

 Ln.IL-6 (pg/ml)

3.76 ± 0.74

3.34 ± 0.62

0.008